{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:33:56Z","timestamp":1747208036452,"version":"3.40.5"},"reference-count":84,"publisher":"Becaris Publishing Limited","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold>Nodal mantle cell lymphoma (NMCL) has a worse survival than extra-nodal mantle cell lymphoma.<jats:bold>Materials &amp; methods:<\/jats:bold>A cohort study was conducted to evaluate the primary site role as a mortality predictor using data from 1983 to 2011 from the Surveillance, Epidemiology, and End Results (SEER) database.<jats:bold>Results:<\/jats:bold>Most patients had NMCL in multiple regions (71.9%). There was a significantly increased incidence of NMCL cases over years with 83.2% of them occurred between 1998 and\u00a02011. The mean survival was 52.9 months with overall survival\/cancer-specific survival rate of 29.2\/42.9%, respectively. Lymph nodes of intrathoracic and multiple regions had a worse overall survival while the head, face and neck, intra-abdominal, pelvic, inguinal region and leg as well as multiple regions had worse cancer-specific survival.<jats:bold>Conclusion:<\/jats:bold>NMCL primary site can serve as a prognostic factor. We encourage adding it to MCL International Prognostic Index.<\/jats:p>","DOI":"10.2217\/cer-2020-0083","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T15:02:01Z","timestamp":1599231721000},"page":"861-876","source":"Crossref","is-referenced-by-count":2,"title":["Using the primary site as a prognostic tool for nodal mantle cell lymphoma: a SEER-based study"],"prefix":"10.57264","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9848-2965","authenticated-orcid":false,"given":"Mohamed Gomaa","family":"Kamel","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Minia University, Minia 61519, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0967-797X","authenticated-orcid":false,"given":"Amr Ehab","family":"El-Qushayri","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Minia University, Minia 61519, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-4580","authenticated-orcid":false,"given":"Ahmed Kamal","family":"Sayed","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Minia University, Minia 61519, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Tien","family":"Huy","sequence":"additional","affiliation":[{"name":"Evidence Based Medicine Research Group, Ton Duc Thang University, Ho Chi Minh City\u00a070000, Vietnam"},{"name":"Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City 70000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"5","key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris NL","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84(5), 1361\u20131392 (1994).","journal-title":"Blood"},{"issue":"12","key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting \u2013 Airlie House, Virginia, November 1997","volume":"17","author":"Harris NL","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting \u2013 Airlie House, Virginia, November 1997. J. Clin. Oncol. 17(12), 3835\u20133849 (1999).","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","article-title":"Mantle cell lymphoma: a retrospective study of 121 cases","volume":"12","author":"Samaha H","year":"1998","unstructured":"Samaha H, Dumontet C, Ketterer N Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 12(8), 1281\u20131287 (1998).","journal-title":"Leukemia"},{"key":"e_1_3_3_6_2","first-page":"9583257","article-title":"Ibrutinib treatment of mantle cell lymphoma relapsing at central nervous system: a case report and literature review","volume":"2017","author":"Mannina D","year":"2017","unstructured":"Mannina D, Loteta B. Ibrutinib treatment of mantle cell lymphoma relapsing at central nervous system: a case report and literature review. Case Rep. Hematol. 2017, 9583257 (2017).","journal-title":"Case Rep. Hematol."},{"issue":"8","key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","article-title":"Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network","volume":"24","author":"Cheah CY","year":"2013","unstructured":"Cheah CY, George A, Gine E Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann. Oncol. 24(8), 2119\u20132123 (2013).","journal-title":"Ann. Oncol."},{"issue":"1","key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/annonc\/mdm447","article-title":"Central nervous system involvement in mantle cell lymphoma","volume":"19","author":"Ferrer A","year":"2008","unstructured":"Ferrer A, Bosch F, Villamor N Central nervous system involvement in mantle cell lymphoma. Ann. Oncol. 19(1), 135\u2013141 (2008).","journal-title":"Ann. Oncol."},{"key":"e_1_3_3_9_2","first-page":"542","volume-title":"ASH Education Program Book","author":"Dreyling M","year":"2009","unstructured":"Dreyling M, Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. In: ASH Education Program Book 2009(1), 542\u2013551 (2009)."},{"issue":"4","key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fernandez V","year":"2010","unstructured":"Fernandez V, Salamero O, Espinet B Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 70(4), 1408\u20131418 (2010).","journal-title":"Cancer Res."},{"issue":"3","key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma","volume":"82","author":"Bosch F","year":"1998","unstructured":"Bosch F, L\u00f3pez-Guillermo A, Campo E Mantle cell lymphoma. Cancer 82(3), 567\u2013575 (1998).","journal-title":"Cancer"},{"issue":"1","key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton LM","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107(1), 265\u2013276 (2006).","journal-title":"Blood"},{"issue":"4","key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou Y","year":"2008","unstructured":"Zhou Y, Wang H, Fang W Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113(4), 791\u2013798 (2008).","journal-title":"Cancer"},{"issue":"6","key":"e_1_3_3_14_2","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1055-9965.EPI-13-0040","article-title":"The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009","volume":"22","author":"Shiels MS","year":"2013","unstructured":"Shiels MS, Engels EA, Linet MS The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009. Cancer Epidemiol. Prev. Biomark. 22(6), 1069\u20131078 (2013).","journal-title":"Cancer Epidemiol. Prev. Biomark."},{"issue":"8","key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3109\/10428194.2012.656628","article-title":"Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007","volume":"53","author":"Chandran R","year":"2012","unstructured":"Chandran R, Gardiner SK, Simon M, Spurgeon SE. Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007. Leuk. Lymphoma 53(8), 1488\u20131493 (2012).","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"e_1_3_3_16_2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou Y","year":"2008","unstructured":"Zhou Y, Wang H, Fang W Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113(4), 791\u2013798 (2008).","journal-title":"Cancer"},{"issue":"6","key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans H","year":"2012","unstructured":"Kluin-Nelemans H, Hoster E, Hermine O Treatment of older patients with mantle-cell lymphoma. N. Engl. J. Med. 367(6), 520\u2013531 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"e_1_3_3_18_2","first-page":"115","article-title":"Mantle-cell lymphoma","volume":"36","author":"Campo E","year":"1999","unstructured":"Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin. Hematol. 36(2), 115\u2013127 (1999).","journal-title":"Semin. Hematol."},{"issue":"1","key":"e_1_3_3_19_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/hupa.2002.30221","article-title":"From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades","volume":"33","author":"Swerdlow SH","year":"2002","unstructured":"Swerdlow SH, Williams ME. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Human Pathol. 33(1), 7\u201320 (2002).","journal-title":"Human Pathol."},{"issue":"8","key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/cncr.27898","article-title":"Using primary site as a predictor of survival in mantle cell lymphoma","volume":"119","author":"Ambinder AJ","year":"2013","unstructured":"Ambinder AJ, Shenoy PJ, Nastoupil LJ, Flowers CR. Using primary site as a predictor of survival in mantle cell lymphoma. Cancer 119(8), 1570\u20131577 (2013).","journal-title":"Cancer"},{"issue":"2","key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald A","year":"2003","unstructured":"Rosenwald A, Wright G, Wiestner A The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3(2), 185\u2013197 (2003).","journal-title":"Cancer Cell"},{"issue":"11","key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.humpath.2005.08.021","article-title":"Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma?","volume":"36","author":"Espinet B","year":"2005","unstructured":"Espinet B, Sol\u00e9 F, Pedro C Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma? Human Pathol. 36(11), 1232\u20131237 (2005).","journal-title":"Human Pathol."},{"issue":"8","key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin P","year":"2009","unstructured":"Martin P, Chadburn A, Christos P Outcome of deferred initial therapy in mantle-cell lymphoma. J. Clin. Oncol. 27(8), 1209\u20131213 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"e_1_3_3_24_2","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1053\/S0046-8177(03)00410-6","article-title":"Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes","volume":"34","author":"Nodit L","year":"2003","unstructured":"Nodit L, Bahler DW, Jacobs SA, Locker J, Swerdlow SH. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Human Pathol. 34(10), 1030\u20131034 (2003).","journal-title":"Human Pathol."},{"issue":"12","key":"e_1_3_3_25_2","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","article-title":"A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease","volume":"101","author":"Orchard J","year":"2003","unstructured":"Orchard J, Garand R, Davis Z A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 101(12), 4975\u20134981 (2003).","journal-title":"Blood"},{"issue":"3","key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1053\/j.semdp.2011.02.010","article-title":"Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers","volume":"28","author":"Sander B","year":"2011","unstructured":"Sander B. Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers. Semin. Diagn. Pathol. 28(3), 245\u2013255 (2011).","journal-title":"Semin. Diagn. Pathol."},{"issue":"2","key":"e_1_3_3_27_2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster E","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111(2), 558\u2013565 (2008).","journal-title":"Blood"},{"issue":"9","key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3324\/haematol.2009.021113","article-title":"Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting","volume":"95","author":"Van De Schans SA","year":"2010","unstructured":"Van De Schans SA, Janssen-Heijnen ML, Nijziel MR, Steyerberg EW, Van Spronsen DJ. Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting. Haematologica 95(9), 1503\u20131509 (2010).","journal-title":"Haematologica"},{"issue":"3","key":"e_1_3_3_29_2","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1007\/s12032-011-0136-1","article-title":"Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study","volume":"29","author":"Todorovic M","year":"2012","unstructured":"Todorovic M, Balint B, Andjelic B Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study. Med. Oncol. 29(3), 2212\u20132219 (2012).","journal-title":"Med. Oncol."},{"issue":"8","key":"e_1_3_3_30_2","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler CH","year":"2010","unstructured":"Geisler CH, Kolstad A, Laurell A The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 115(8), 1530\u20131533 (2010).","journal-title":"Blood"},{"issue":"3","key":"e_1_3_3_31_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2011.06.001","article-title":"Prognostic relevance of clinical risk factors in mantle cell lymphoma","volume":"48","author":"Hoster E","year":"2011","unstructured":"Hoster E. Prognostic relevance of clinical risk factors in mantle cell lymphoma. Semin. Hematol. 48(3), 185\u2013188 (2011).","journal-title":"Semin. Hematol."},{"issue":"4","key":"e_1_3_3_32_2","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":"Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group","volume":"111","author":"Determann O","year":"2008","unstructured":"Determann O, Hoster E, Ott G Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 111(4), 2385\u20132387 (2008).","journal-title":"Blood"},{"issue":"10","key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","article-title":"p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis","volume":"87","author":"Greiner TC","year":"1996","unstructured":"Greiner TC, Moynihan MJ, Chan WC p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87(10), 4302\u20134310 (1996).","journal-title":"Blood"},{"issue":"8","key":"e_1_3_3_34_2","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351","article-title":"p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas","volume":"87","author":"Hernandez L","year":"1996","unstructured":"Hernandez L, Fest T, Cazorla M p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87(8), 3351\u20133359 (1996).","journal-title":"Blood"},{"issue":"12","key":"e_1_3_3_35_2","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","article-title":"A subset of t (11; 14) lymphoma with mantle cell features displays mutated IgV H genes and includes patients with good prognosis, nonnodal disease","volume":"101","author":"Orchard J","year":"2003","unstructured":"Orchard J, Garand R, Davis Z A subset of t (11; 14) lymphoma with mantle cell features displays mutated IgV H genes and includes patients with good prognosis, nonnodal disease. Blood 101(12), 4975\u20134981 (2003).","journal-title":"Blood"},{"issue":"4","key":"e_1_3_3_36_2","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fern\u00e0ndez V","year":"2010","unstructured":"Fern\u00e0ndez V, Salamero O, Espinet B Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 70(4), 1408\u20131418 (2010).","journal-title":"Cancer Res."},{"issue":"8","key":"e_1_3_3_37_2","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","article-title":"Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis","volume":"96","author":"Ondrejka SL","year":"2011","unstructured":"Ondrejka SL, Lai R, Smith SD, Hsi ED. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 96(8), 1121\u20131127 (2011).","journal-title":"Haematologica"},{"issue":"8","key":"e_1_3_3_38_2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2011.047357","article-title":"Indolent mantle cell lymphoma","volume":"96","author":"Furtado M","year":"2011","unstructured":"Furtado M, Rule S. Indolent mantle cell lymphoma. Haematologica 96(8), 1086\u20131088 (2011).","journal-title":"Haematologica"},{"issue":"3","key":"e_1_3_3_39_2","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1080\/10428194.2017.1357175","article-title":"Comparison of two doses of intravenous temsirolimus in patients with relapsed\/refractory mantle cell lymphoma","volume":"59","author":"Jurczak W","year":"2018","unstructured":"Jurczak W, Ramanathan S, Giri P Comparison of two doses of intravenous temsirolimus in patients with relapsed\/refractory mantle cell lymphoma. Leuk. Lymphoma 59(3), 670\u2013678 (2018).","journal-title":"Leuk. Lymphoma"},{"issue":"20","key":"e_1_3_3_40_2","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1182\/blood-2010-06-289561","article-title":"InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions","volume":"116","author":"Turner JJ","year":"2010","unstructured":"Turner JJ, Morton LM, Linet MS InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood 116(20), e90\u2013e98 (2010).","journal-title":"Blood"},{"issue":"2","key":"e_1_3_3_41_2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1182\/blood-2006-11-051672","article-title":"Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph)","volume":"110","author":"Morton LM","year":"2007","unstructured":"Morton LM, Turner JJ, Cerhan JR Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 110(2), 695\u2013708 (2007).","journal-title":"Blood"},{"issue":"3","key":"e_1_3_3_42_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0959-8049(01)00366-5","article-title":"A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors","volume":"38","author":"Andersen N","year":"2002","unstructured":"Andersen N, Jensen M, De Nully Brown P, Geisler C. A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur. J. Cancer 38(3), 401\u2013408 (2002).","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"e_1_3_3_43_2","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.1996.14.4.1269","article-title":"Mantle-cell lymphoma: a population-based clinical study","volume":"14","author":"Velders G","year":"1996","unstructured":"Velders G, Kluin-Nelemans J, De Boer C Mantle-cell lymphoma: a population-based clinical study. J. Clin. Oncol. 14(4), 1269\u20131274 (1996).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"e_1_3_3_44_2","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1200\/JCO.1988.6.12.1838","article-title":"The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin\u2019s lymphoma","volume":"6","author":"Vose JM","year":"1988","unstructured":"Vose JM, Armitage J, Weisenburger D The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin\u2019s lymphoma. J. Clin. Oncol. 6(12), 1838\u20131844 (1988).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"e_1_3_3_45_2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1532-5415.1984.tb02020.x","article-title":"Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age","volume":"32","author":"Armitage JO","year":"1984","unstructured":"Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J. Am. Geriatrics Soc. 32(4), 269\u2013273 (1984).","journal-title":"J. Am. Geriatrics Soc."},{"issue":"15","key":"e_1_3_3_46_2","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/cncr.30068","article-title":"Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma","volume":"122","author":"Cohen JB","year":"2016","unstructured":"Cohen JB, Han X, Jemal A, Ward EM, Flowers CR. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. Cancer 122(15), 2356\u20132363 (2016).","journal-title":"Cancer"},{"issue":"26","key":"e_1_3_3_47_2","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2009.27.0579","article-title":"Impact of age, sex, and comorbidity on cancer therapy and disease progression","volume":"28","author":"Pal SK","year":"2010","unstructured":"Pal SK, Hurria A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J. Clin. Oncol. 28(26), 4086\u20134093 (2010).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"e_1_3_3_48_2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1600-0609.2010.01541.x","article-title":"Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy","volume":"86","author":"Riihij\u00e4rvi S","year":"2011","unstructured":"Riihij\u00e4rvi S, Taskinen M, Jerkeman M, Lepp\u00e4 S. Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur. J. Haematol. 86(2), 124\u2013128 (2011).","journal-title":"Eur. J. Haematol."},{"key":"e_1_3_3_49_2","article-title":"Examined and positive lymph node counts are associated with mortality in prostate cancer: a population-based analysis","author":"Kamel MG","year":"2020","unstructured":"Kamel MG, Istanbuly S, Abd-Elhay Fa-E Examined and positive lymph node counts are associated with mortality in prostate cancer: a population-based analysis. Urol. Int. doi:10.1159\/000505410 (2020) (Epub ahead of print).","journal-title":"Urol. Int."},{"issue":"1","key":"e_1_3_3_50_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/14737140.2018.1409626","article-title":"Cardiovascular mortality trends in non-Hodgkin's lymphoma: a population-based cohort study","volume":"18","author":"Kamel MG","year":"2018","unstructured":"Kamel MG, El-Qushayri AE, Thach TQ, Huy NT. Cardiovascular mortality trends in non-Hodgkin's lymphoma: a population-based cohort study. Expert Rev. Anticancer Ther. 18(1), 91\u2013100 (2018).","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"8","key":"e_1_3_3_51_2","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/hed.25742","article-title":"Examined and positive lymph nodes counts and lymph nodes ratio are associated with survival in major salivary gland cancer","volume":"41","author":"Elhusseiny KM","year":"2019","unstructured":"Elhusseiny KM, Abd-Elhay FA, Kamel MG Examined and positive lymph nodes counts and lymph nodes ratio are associated with survival in major salivary gland cancer. Head Neck 41(8), 2625\u20132635 (2019).","journal-title":"Head Neck"},{"issue":"6","key":"e_1_3_3_52_2","doi-asserted-by":"crossref","first-page":"e1293","DOI":"10.1016\/j.clbc.2018.07.003","article-title":"Negative lymph node count and lymph node ratio are associated with survival in male breast cancer","volume":"18","author":"Abd-Elhay FA","year":"2018","unstructured":"Abd-Elhay FA, Elhusseiny KM, Kamel MG Negative lymph node count and lymph node ratio are associated with survival in male breast cancer. Clin. Breast Cancer 18(6), e1293\u2013e1310 (2018).","journal-title":"Clin. Breast Cancer"},{"key":"e_1_3_3_53_2","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.clml.2014.04.013","article-title":"Effect of radiotherapy on the survival of patients with stage I and stage II mantle cell lymphoma: analysis of the Surveillance, Epidemiology and End Results database","volume":"14","author":"Guru Murthy GS","year":"2014","unstructured":"Guru Murthy GS, Venkitachalam R, Mehta P. Effect of radiotherapy on the survival of patients with stage I and stage II mantle cell lymphoma: analysis of the Surveillance, Epidemiology and End Results database. Clin. Lymphoma Myeloma Leuk. 14(Suppl.), S90\u2013S95 (2014).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"16","key":"e_1_3_3_54_2","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1016\/j.ejca.2006.04.018","article-title":"Treatment and survival for non-Hodgkin\u2019s lymphoma: influence of histological subtype, age, and other factors in a population-based study (1999-2001)","volume":"42","author":"Cronin-Fenton DP","year":"2006","unstructured":"Cronin-Fenton DP, Sharp L, Deady S, Comber H. Treatment and survival for non-Hodgkin\u2019s lymphoma: influence of histological subtype, age, and other factors in a population-based study (1999-2001). Eur. J. Cancer 42(16), 2786\u20132793 (2006).","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"e_1_3_3_55_2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/bjc.1985.258","article-title":"Non-Hodgkin\u2019s lymphomas in never married men in Los Angeles","volume":"52","author":"Ross R","year":"1985","unstructured":"Ross R, Dworsky R, Paganini-Hill A, Levine A, Mack T. Non-Hodgkin\u2019s lymphomas in never married men in Los Angeles. Brit. J. Cancer 52(5), 785 (1985).","journal-title":"Brit. J. Cancer"},{"issue":"31","key":"e_1_3_3_56_2","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1200\/JCO.2013.49.6489","article-title":"Marital status and survival in patients with cancer","volume":"31","author":"Aizer AA","year":"2013","unstructured":"Aizer AA, Chen M-H, Mccarthy EP Marital status and survival in patients with cancer. J. Clin. Oncol. 31(31), 3869\u20133876 (2013).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"e_1_3_3_57_2","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/10428190802455867","article-title":"Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States","volume":"49","author":"Abouyabis AN","year":"2008","unstructured":"Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk. Lymphoma 49(11), 2099\u20132107 (2008).","journal-title":"Leuk. Lymphoma"},{"issue":"18","key":"e_1_3_3_58_2","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2001.19.18.3874","article-title":"Primary gastrointestinal non-Hodgkin\u2019s lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma-results of the prospective German Multicenter Study GIT NHL 01\/92","volume":"19","author":"Koch P","year":"2001","unstructured":"Koch P, Del Valle F, Berdel WE Primary gastrointestinal non-Hodgkin\u2019s lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma-results of the prospective German Multicenter Study GIT NHL 01\/92. J. Clin. Oncol. 19(18), 3874\u20133883 (2001).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"e_1_3_3_59_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0360-3016(83)90200-6","article-title":"Curability of gastrointestinal lymphoma with combined surgery and radiation","volume":"9","author":"Gospodarowicz MK","year":"1983","unstructured":"Gospodarowicz MK, Bush R, Brown J, Chua T. Curability of gastrointestinal lymphoma with combined surgery and radiation. Int. J. Radiat. Oncol. Biol. Phys. 9(1), 3\u20139 (1983).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"e_1_3_3_60_2","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/1097-0142(19820315)49:6<1135::AID-CNCR2820490612>3.0.CO;2-E","article-title":"The role of surgery in the management of gastric lymphoma","volume":"49","author":"Fleming ID","year":"1982","unstructured":"Fleming ID, Mitchell S, Dilawari RA. The role of surgery in the management of gastric lymphoma. Cancer 49(6), 1135\u20131141 (1982).","journal-title":"Cancer"},{"issue":"4","key":"e_1_3_3_61_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.1983.1.4.263","article-title":"Large cell lymphomas of the stomach: improved prognosis with complete resection of all intrinsic gastrointestinal disease","volume":"1","author":"Paulson S","year":"1983","unstructured":"Paulson S, Sheehan R, Stone M, Frenkel E. Large cell lymphomas of the stomach: improved prognosis with complete resection of all intrinsic gastrointestinal disease. J. Clin. Oncol. 1(4), 263\u2013269 (1983).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_62_2","first-page":"206","volume-title":"Non-Hodgkin's Lymphomas: New Techniques and Treatments.","author":"Herrera A","year":"1985","unstructured":"Herrera A, Solal-Celigny P, Bernard J. High-risk primary lymphomas of the digestive tract: therapeutic results and study of prognostic factors. In: Non-Hodgkin's Lymphomas: New Techniques and Treatments. Sotto JJ, Vrousos C, Sotto M-F, Vincent F (Eds). Karger Publishers 206\u2013209 (1985)."},{"issue":"5","key":"e_1_3_3_63_2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/1097-0142(19850301)55:5<1060::AID-CNCR2820550523>3.0.CO;2-8","article-title":"Primary gastrointestinal non-Hodgkin\u2019s lymphomas. A retrospective clinicopathologic study of 150 cases","volume":"55","author":"Dragosics B","year":"1985","unstructured":"Dragosics B, Bauer P, Radaszkiewicz T. Primary gastrointestinal non-Hodgkin\u2019s lymphomas. A retrospective clinicopathologic study of 150 cases. Cancer 55(5), 1060\u20131073 (1985).","journal-title":"Cancer"},{"issue":"8","key":"e_1_3_3_64_2","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/1097-0142(19800415)45:8<2188::AID-CNCR2820450830>3.0.CO;2-E","article-title":"Diffuse histiocytic lymphoma presenting with gastrointestinal tract lesions the stanford experience","volume":"45","author":"Rosenfelt F","year":"1980","unstructured":"Rosenfelt F, Rosenberg SA. Diffuse histiocytic lymphoma presenting with gastrointestinal tract lesions the stanford experience. Cancer 45(8), 2188\u20132193 (1980).","journal-title":"Cancer"},{"issue":"4","key":"e_1_3_3_65_2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000226480","article-title":"Primary gastrointestinal lymphoma","volume":"44","author":"Ampil F","year":"1987","unstructured":"Ampil F. Primary gastrointestinal lymphoma. Oncology 44(4), 214\u2013218 (1987).","journal-title":"Oncology"},{"issue":"3","key":"e_1_3_3_66_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/bjc.1985.206","article-title":"Primary gastric lymphoma \u2013 the experience of a general hospital","volume":"52","author":"Economopoulos T","year":"1985","unstructured":"Economopoulos T, Alexopoulos C, Stathakis N Primary gastric lymphoma \u2013 the experience of a general hospital. Brit. J. Cancer 52(3), 391 (1985).","journal-title":"Brit. J. Cancer"},{"issue":"4","key":"e_1_3_3_67_2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.1985.3.4.495","article-title":"Non-Hodgkin\u2019s lymphoma of the stomach: a prospective pilot study of surgery plus chemotherapy in early and advanced disease","volume":"3","author":"Sheridan WP","year":"1985","unstructured":"Sheridan WP, Medley G, Brodie GN. Non-Hodgkin\u2019s lymphoma of the stomach: a prospective pilot study of surgery plus chemotherapy in early and advanced disease. J. Clin. Oncol. 3(4), 495\u2013500 (1985).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"e_1_3_3_68_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/hon.2900050206","article-title":"Gastrointestinal lymphoma in Chinese: a retrospective analysis","volume":"5","author":"Liang R","year":"1987","unstructured":"Liang R, Todd D, Chan T, Ng R, Ho F. Gastrointestinal lymphoma in Chinese: a retrospective analysis. Hematol. Oncol. 5(2), 115\u2013126 (1987).","journal-title":"Hematol. Oncol."},{"issue":"10","key":"e_1_3_3_69_2","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/0277-5379(85)90015-X","article-title":"A prospective study of the treatment of high-grade histology non-Hodgkin\u2019s lymphoma involving the gastrointestinal tract","volume":"21","author":"Steward WP","year":"1985","unstructured":"Steward WP, Harris M, Wagstaff J A prospective study of the treatment of high-grade histology non-Hodgkin\u2019s lymphoma involving the gastrointestinal tract. Eur. J. Cancer Clin. Oncol. 21(10), 1195\u20131200 (1985).","journal-title":"Eur. J. Cancer Clin. Oncol."},{"issue":"7","key":"e_1_3_3_70_2","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.1988.6.7.1125","article-title":"Non-Hodgkin\u2019s lymphoma of the gastrointestinal tract: an analysis of clinical and pathologic features affecting outcome","volume":"6","author":"List AF","year":"1988","unstructured":"List AF, Greer J, Cousar J Non-Hodgkin\u2019s lymphoma of the gastrointestinal tract: an analysis of clinical and pathologic features affecting outcome. J. Clin. Oncol. 6(7), 1125\u20131133 (1988).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"e_1_3_3_71_2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1200\/JCO.1988.6.2.253","article-title":"Chemotherapy following surgery for stages IE and IIE non-Hodgkin\u2019s lymphoma of the gastrointestinal tract","volume":"6","author":"Shepherd FA","year":"1988","unstructured":"Shepherd FA, Evans W, Kutas G Chemotherapy following surgery for stages IE and IIE non-Hodgkin\u2019s lymphoma of the gastrointestinal tract. J. Clin. Oncol. 6(2), 253\u2013260 (1988).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"e_1_3_3_72_2","first-page":"599","article-title":"Surgical resection and limited chemotherapy for abdominal undifferentiated lymphomas","volume":"68","author":"Janus C","year":"1984","unstructured":"Janus C, Edwards B, Sariban E, Magrath I. Surgical resection and limited chemotherapy for abdominal undifferentiated lymphomas. Cancer Treat. Rep. 68(4), 599\u2013605 (1984).","journal-title":"Cancer Treat. Rep."},{"key":"e_1_3_3_73_2","first-page":"1","article-title":"Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility","author":"Guidot DM","year":"2017","unstructured":"Guidot DM, Switchenko JM, Nastoupil LJ Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. Leuk. Lymphoma doi:10.1080\/10428194.2017.1361032 1\u20138 (2017) (Epub ahead of print).","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"e_1_3_3_74_2","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized Phase II multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler CH","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized Phase II multicenter study by the Nordic Lymphoma Group. Blood 112(7), 2687\u20132693 (2008).","journal-title":"Blood"},{"issue":"9","key":"e_1_3_3_75_2","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":"Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network","volume":"17","author":"Kahl BS","year":"2006","unstructured":"Kahl BS, Longo WL, Eickhoff JC Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann. Oncol. 17(9), 1418\u20131423 (2006).","journal-title":"Ann. Oncol."},{"issue":"1","key":"e_1_3_3_76_2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.critrevonc.2011.05.001","article-title":"Mantle cell lymphoma","volume":"82","author":"Cortelazzo S","year":"2012","unstructured":"Cortelazzo S, Ponzoni M, Ferreri AJ, Dreyling M. Mantle cell lymphoma. Crit. Rev. Oncol. Hematol. 82(1), 78\u2013101 (2012).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"11","key":"e_1_3_3_77_2","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma","volume":"89","author":"Armitage JO","year":"1997","unstructured":"Armitage JO. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. Blood 89(11), 3909\u20133918 (1997).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_3_78_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","article-title":"Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network","volume":"131","author":"Tiemann M","year":"2005","unstructured":"Tiemann M, Schrader C, Klapper W Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Brit. J. Haematol. 131(1), 29\u201338 (2005).","journal-title":"Brit. J. Haematol."},{"issue":"6","key":"e_1_3_3_79_2","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V89.6.2067","article-title":"Mantle cell lymphoma: a clinicopathologic study of 80 cases","volume":"89","author":"Argatoff LH","year":"1997","unstructured":"Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 89(6), 2067\u20132078 (1997).","journal-title":"Blood"},{"issue":"4","key":"e_1_3_3_80_2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s12029-014-9655-2","article-title":"Primary gastrointestinal mantle cell lymphoma: a retrospective study","volume":"45","author":"Dasappa L","year":"2014","unstructured":"Dasappa L, Suresh Babu MC, Sirsath NT Primary gastrointestinal mantle cell lymphoma: a retrospective study. J. Gastrointest. Cancer 45(4), 481\u2013486 (2014).","journal-title":"J. Gastrointest. Cancer"},{"issue":"10","key":"e_1_3_3_81_2","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1097\/01.pas.0000208899.15859.cb","article-title":"Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study","volume":"30","author":"Salar A","year":"2006","unstructured":"Salar A, Juanpere N, Bellosillo B Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am. J. Surg. Pathol. 30(10), 1274\u20131280 (2006).","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"e_1_3_3_82_2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/bjc.1993.141","article-title":"Primary gastrointestinal non-Hodgkin\u2019s lymphoma: a review of 175 British National Lymphoma Investigation cases","volume":"67","author":"Morton JE","year":"1993","unstructured":"Morton JE, Leyland MJ, Vaughan Hudson G Primary gastrointestinal non-Hodgkin\u2019s lymphoma: a review of 175 British National Lymphoma Investigation cases. Br. J. Cancer 67(4), 776\u2013782 (1993).","journal-title":"Br. J. Cancer"},{"issue":"13","key":"e_1_3_3_83_2","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1538-7445.AM2018-2215","article-title":"The role of primary lymph node sites in survival and mortality prediction in DLBCL: a SEER population-based retrospective study [abstract]","volume":"78","author":"Kamel MG","year":"2018","unstructured":"Kamel MG, Abd-Elhay FA, Morsy S The role of primary lymph node sites in survival and mortality prediction in DLBCL: a SEER population-based retrospective study [abstract]. Cancer Res. 78(Suppl. 13), 2215 (2018).","journal-title":"Cancer Res."},{"issue":"3","key":"e_1_3_3_84_2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ajh.23638","article-title":"Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database","volume":"89","author":"Castillo JJ","year":"2014","unstructured":"Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am. J. Hematol. 89(3), 310\u2013314 (2014).","journal-title":"Am. J. Hematol."},{"issue":"4","key":"e_1_3_3_85_2","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/cam4.1280","article-title":"The role of primary lymph node sites in survival and mortality prediction in Hodgkin lymphoma: a SEER population-based retrospective study","volume":"7","author":"Ebied A","year":"2018","unstructured":"Ebied A, Thanh Huan V, Makram OM The role of primary lymph node sites in survival and mortality prediction in Hodgkin lymphoma: a SEER population-based retrospective study. Cancer Med. 7(4), 953\u2013965 (2018).","journal-title":"Cancer Med."},{"issue":"20","key":"e_1_3_3_86_2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow SH","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20), 2375\u20132390 (2016).","journal-title":"Blood"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2020-0083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T21:50:14Z","timestamp":1696629014000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2020-0083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":84,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.2217\/cer-2020-0083"],"URL":"https:\/\/doi.org\/10.2217\/cer-2020-0083","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}